{
    "info": {
        "nct_id": "NCT04777994",
        "official_title": "A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors",
        "inclusion_criteria": "* Must weigh at least 35 kilograms (kg).\n* An Eastern Cooperative Oncology Group (ECOG) performance status <= 2.\n* Life expectancy of >= 12 weeks.\n* Laboratory values meeting protocol criteria.\n* QT interval corrected for heart rate < 470 msec (using Fridericia's correction), and no clinically significant electrocardiographic findings.\n* Measurable disease defined by RECIST 1.1 criteria.\n\nFor Monotherapy and Combination Dose Escalation:\n\n* Participants with histologically or cytologically proven metastatic or locally advanced tumors, for which no effective standard therapy exists, or where standard therapy has failed. Participants must have received at least 1 prior systemic anticancer therapy for the indication being considered.\n\nFor Monotherapy Dose Expansion only:\n\n* Participants must have received at least 1 prior line containing PD-1/PD-L1 targeted therapy with a best response by RECIST v1.1 of CR/PR/stable (any duration) or stable disease (for greater than 6 months); AND\n* Must have been previously treated with 1 or more prior lines of therapy in the locally advanced or metastatic setting with the following tumor types:\n\n  * Relapsed/refractory HNSCC\n  * Relapsed/refractory NSCLC\n  * Advanced ccRCC\n\nFor PD-1 Targeting Agent Combination Dose Expansion only:\n\n* For the following tumor types, subject must have received at least 1 prior line containing PD-1/PD-L1 targeted therapy with response by RECIST v1.1 of CR/PR (any duration) or stable disease (for greater than 6 months):\n\n  * Relapsed HNSCC\n  * Relapsed NSCLC\n  * Relapsed Advanced ccRCC\n* For the following tumor types, subject must have received at least 1 prior line containing PD-1/PD-L1 targeted therapy and have had disease progression with PD-1/PD-L1 targeted therapy:\n\n  * Locally Advanced or metastatic MSI-H tumors\n\nFor VEGFR TKI Combination Dose Expansion only:\n\n* Relapsed advance ccRCC with no more than 1 prior VEGFR TKI\n* Participants no recent history of hemorrhage, including hemoptysis, hematemesis, or melena\n* Participants with poorly controlled hypertension are excluded.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Untreated brain or meningeal metastases (i.e., subjects with history of metastases are eligible provided they do not require ongoing steroid treatment and have shown clinical and radiographic stability for at least 28 days after definitive therapy)\n* Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.\n* Unresolved Grade 2 or higher peripheral neuropathy.\n* History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.\n* Recent history (within 6 months) of congestive heart failure (defined as New York Heart Association, Class 2 or higher), ischemic cardiovascular event, pericarditis, or clinically significant pericardial effusion or arrythmia.\n* Recent history (within 6 months) of Childs-Pugh B or C classification of liver disease.\n* History of clinically significant medical and/or psychiatric conditions or any other reason that, in the opinion of the investigator, would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study drug.\n* History of uncontrolled, clinically significant endocrinopathy.\n* Known gastrointestinal disorders making absorption of oral medications problematic; subject must be able to swallow capsules.\n* If treated with a PD-1/aPD-L1 targeting or other immune-oncology agents in the past, excluded if had prior pneumonitis, prior Grade 3 or higher immune mediated toxicity, hypersensitivity to administered drug or drug related toxicity requiring discontinuation.\n* Active autoimmune disease requiring systemic treatment in past 2-years (exceptions for endocrinopathies, vitiligo or atopic conditions).\n* History of solid organ transplant or allogeneic stem cell transplant.\n* History of other malignancy, with the following exceptions:\n\n  * No known active disease present within >= 3 years before first dose of study treatment and felt to be at low recurrence by investigator.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated carcinoma in situ without evidence of disease.\n* History of interstitial lung disease or pneumonitis.\n* Major surgery <= 28 days prior to first dose of study drug\n* Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection per local testing practices.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Participants no recent history of hemorrhage, including hemoptysis, hematemesis, or melena",
            "criterions": [
                {
                    "exact_snippets": "no recent history of hemorrhage",
                    "criterion": "history of hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoptysis",
                    "criterion": "history of hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hematemesis",
                    "criterion": "history of hematemesis",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "melena",
                    "criterion": "history of melena",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Laboratory values meeting protocol criteria.",
            "criterions": [
                {
                    "exact_snippets": "Laboratory values meeting protocol criteria",
                    "criterion": "laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "meets protocol criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* An Eastern Cooperative Oncology Group (ECOG) performance status <= 2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status <= 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed Advanced ccRCC",
            "criterions": [
                {
                    "exact_snippets": "Relapsed Advanced ccRCC",
                    "criterion": "ccRCC (clear cell renal cell carcinoma)",
                    "requirements": [
                        {
                            "requirement_type": "disease subtype",
                            "expected_value": "clear cell renal cell carcinoma"
                        }
                    ]
                },
                {
                    "exact_snippets": "Relapsed Advanced ccRCC",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "relapsed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "advanced",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed NSCLC",
            "criterions": [
                {
                    "exact_snippets": "Relapsed NSCLC",
                    "criterion": "NSCLC (non-small cell lung cancer)",
                    "requirements": [
                        {
                            "requirement_type": "relapsed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of >= 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of >= 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "For Monotherapy Dose Expansion only:",
            "criterions": [
                {
                    "exact_snippets": "For Monotherapy Dose Expansion only",
                    "criterion": "monotherapy dose expansion cohort participation",
                    "requirements": [
                        {
                            "requirement_type": "cohort participation",
                            "expected_value": "monotherapy dose expansion only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced ccRCC",
            "criterions": [
                {
                    "exact_snippets": "Advanced ccRCC",
                    "criterion": "ccRCC (clear cell renal cell carcinoma)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must weigh at least 35 kilograms (kg).",
            "criterions": [
                {
                    "exact_snippets": "Must weigh at least 35 kilograms (kg)",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 35,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "For VEGFR TKI Combination Dose Expansion only:",
            "criterions": [
                {
                    "exact_snippets": "For VEGFR TKI Combination Dose Expansion only",
                    "criterion": "trial cohort assignment",
                    "requirements": [
                        {
                            "requirement_type": "cohort",
                            "expected_value": "VEGFR TKI Combination Dose Expansion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For the following tumor types, subject must have received at least 1 prior line containing PD-1/PD-L1 targeted therapy and have had disease progression with PD-1/PD-L1 targeted therapy:",
            "criterions": [
                {
                    "exact_snippets": "subject must have received at least 1 prior line containing PD-1/PD-L1 targeted therapy",
                    "criterion": "prior PD-1/PD-L1 targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": [
                                "PD-1 targeted therapy",
                                "PD-L1 targeted therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have had disease progression with PD-1/PD-L1 targeted therapy",
                    "criterion": "disease progression with PD-1/PD-L1 targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": [
                                "PD-1 targeted therapy",
                                "PD-L1 targeted therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Locally Advanced or metastatic MSI-H tumors",
            "criterions": [
                {
                    "exact_snippets": "Locally Advanced or metastatic MSI-H tumors",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "MSI-H tumors",
                    "criterion": "microsatellite instability status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "MSI-H"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with poorly controlled hypertension are excluded.",
            "criterions": [
                {
                    "exact_snippets": "poorly controlled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "not poorly controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For the following tumor types, subject must have received at least 1 prior line containing PD-1/PD-L1 targeted therapy with response by RECIST v1.1 of CR/PR (any duration) or stable disease (for greater than 6 months):",
            "criterions": [
                {
                    "exact_snippets": "subject must have received at least 1 prior line containing PD-1/PD-L1 targeted therapy",
                    "criterion": "prior PD-1/PD-L1 targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": "PD-1/PD-L1 targeted therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "response by RECIST v1.1 of CR/PR (any duration) or stable disease (for greater than 6 months)",
                    "criterion": "response to prior PD-1/PD-L1 targeted therapy (by RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "response type",
                            "expected_value": [
                                "CR",
                                "PR"
                            ]
                        },
                        {
                            "requirement_type": "response duration",
                            "expected_value": "any duration"
                        }
                    ]
                },
                {
                    "exact_snippets": "response by RECIST v1.1 of ... stable disease (for greater than 6 months)",
                    "criterion": "response to prior PD-1/PD-L1 targeted therapy (by RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "response type",
                            "expected_value": "stable disease"
                        },
                        {
                            "requirement_type": "response duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "For PD-1 Targeting Agent Combination Dose Expansion only:",
            "criterions": [
                {
                    "exact_snippets": "For PD-1 Targeting Agent Combination Dose Expansion only",
                    "criterion": "cohort assignment",
                    "requirements": [
                        {
                            "requirement_type": "cohort",
                            "expected_value": "PD-1 Targeting Agent Combination Dose Expansion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed/refractory NSCLC",
            "criterions": [
                {
                    "exact_snippets": "Relapsed/refractory NSCLC",
                    "criterion": "NSCLC (non-small cell lung cancer)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed HNSCC",
            "criterions": [
                {
                    "exact_snippets": "Relapsed HNSCC",
                    "criterion": "head and neck squamous cell carcinoma (HNSCC)",
                    "requirements": [
                        {
                            "requirement_type": "relapsed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* QT interval corrected for heart rate < 470 msec (using Fridericia's correction), and no clinically significant electrocardiographic findings.",
            "criterions": [
                {
                    "exact_snippets": "QT interval corrected for heart rate < 470 msec (using Fridericia's correction)",
                    "criterion": "QT interval corrected for heart rate",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no clinically significant electrocardiographic findings",
                    "criterion": "electrocardiographic findings",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed advance ccRCC with no more than 1 prior VEGFR TKI",
            "criterions": [
                {
                    "exact_snippets": "Relapsed advance ccRCC",
                    "criterion": "clear cell renal cell carcinoma (ccRCC)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "relapsed"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "no more than 1 prior VEGFR TKI",
                    "criterion": "prior VEGFR TKI therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed/refractory HNSCC",
            "criterions": [
                {
                    "exact_snippets": "Relapsed/refractory HNSCC",
                    "criterion": "head and neck squamous cell carcinoma (HNSCC)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have received at least 1 prior line containing PD-1/PD-L1 targeted therapy with a best response by RECIST v1.1 of CR/PR/stable (any duration) or stable disease (for greater than 6 months); AND",
            "criterions": [
                {
                    "exact_snippets": "Participants must have received at least 1 prior line containing PD-1/PD-L1 targeted therapy",
                    "criterion": "prior PD-1/PD-L1 targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": [
                                "PD-1 targeted therapy",
                                "PD-L1 targeted therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "best response by RECIST v1.1 of CR/PR/stable (any duration) or stable disease (for greater than 6 months)",
                    "criterion": "best response to prior therapy (by RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "response category",
                            "expected_value": [
                                "CR",
                                "PR",
                                "stable disease"
                            ]
                        },
                        {
                            "requirement_type": "duration for stable disease",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with histologically or cytologically proven metastatic or locally advanced tumors, for which no effective standard therapy exists, or where standard therapy has failed. Participants must have received at least 1 prior systemic anticancer therapy for the indication being considered.",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically proven metastatic or locally advanced tumors",
                    "criterion": "tumor diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "metastatic",
                                "locally advanced"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for which no effective standard therapy exists, or where standard therapy has failed",
                    "criterion": "standard therapy status",
                    "requirements": [
                        {
                            "requirement_type": "standard therapy availability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "standard therapy failure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have received at least 1 prior systemic anticancer therapy for the indication being considered",
                    "criterion": "prior systemic anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease defined by RECIST 1.1 criteria.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease defined by RECIST 1.1 criteria",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have been previously treated with 1 or more prior lines of therapy in the locally advanced or metastatic setting with the following tumor types:",
            "criterions": [
                {
                    "exact_snippets": "Must have been previously treated with 1 or more prior lines of therapy",
                    "criterion": "prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the locally advanced or metastatic setting",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "with the following tumor types",
                    "criterion": "tumor type",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Recent history (within 6 months) of congestive heart failure (defined as New York Heart Association, Class 2 or higher), ischemic cardiovascular event, pericarditis, or clinically significant pericardial effusion or arrythmia.",
            "criterions": [
                {
                    "exact_snippets": "Recent history (within 6 months) of congestive heart failure (defined as New York Heart Association, Class 2 or higher)",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "NYHA_class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Recent history (within 6 months) of ... ischemic cardiovascular event",
                    "criterion": "ischemic cardiovascular event",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Recent history (within 6 months) of ... pericarditis",
                    "criterion": "pericarditis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Recent history (within 6 months) of ... clinically significant pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Recent history (within 6 months) of ... arrythmia",
                    "criterion": "arrythmia",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No known active disease present within >= 3 years before first dose of study treatment and felt to be at low recurrence by investigator.",
            "criterions": [
                {
                    "exact_snippets": "No known active disease present within >= 3 years before first dose of study treatment",
                    "criterion": "active disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time since last active disease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "felt to be at low recurrence by investigator",
                    "criterion": "risk of recurrence",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": "low"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of interstitial lung disease or pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "History of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresolved Grade 2 or higher peripheral neuropathy.",
            "criterions": [
                {
                    "exact_snippets": "Unresolved Grade 2 or higher peripheral neuropathy",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "resolution_status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated carcinoma in situ without evidence of disease.",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated carcinoma in situ",
                    "criterion": "carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "without evidence of disease",
                    "criterion": "evidence of disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of solid organ transplant or allogeneic stem cell transplant.",
            "criterions": [
                {
                    "exact_snippets": "History of solid organ transplant",
                    "criterion": "solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... allogeneic stem cell transplant",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of clinically significant medical and/or psychiatric conditions or any other reason that, in the opinion of the investigator, would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study drug.",
            "criterions": [
                {
                    "exact_snippets": "History of clinically significant medical and/or psychiatric conditions",
                    "criterion": "clinically significant medical and/or psychiatric conditions",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any other reason that, in the opinion of the investigator, would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study drug",
                    "criterion": "any other reason that would interfere with participation or suitability for study drug (per investigator opinion)",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": "would interfere with participation or make unsuitable for study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection per local testing practices.",
            "criterions": [
                {
                    "exact_snippets": "Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection",
                    "criterion": "SARS-CoV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery <= 28 days prior to first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Major surgery <= 28 days prior to first dose of study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Untreated brain or meningeal metastases (i.e., subjects with history of metastases are eligible provided they do not require ongoing steroid treatment and have shown clinical and radiographic stability for at least 28 days after definitive therapy)",
            "criterions": [
                {
                    "exact_snippets": "Untreated brain or meningeal metastases",
                    "criterion": "brain or meningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "no untreated metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with history of metastases are eligible provided they do not require ongoing steroid treatment",
                    "criterion": "ongoing steroid treatment for metastases",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have shown clinical and radiographic stability for at least 28 days after definitive therapy",
                    "criterion": "clinical and radiographic stability after definitive therapy for metastases",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known gastrointestinal disorders making absorption of oral medications problematic; subject must be able to swallow capsules.",
            "criterions": [
                {
                    "exact_snippets": "Known gastrointestinal disorders making absorption of oral medications problematic",
                    "criterion": "gastrointestinal disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "effect on absorption of oral medications",
                            "expected_value": "not problematic"
                        }
                    ]
                },
                {
                    "exact_snippets": "subject must be able to swallow capsules",
                    "criterion": "ability to swallow capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of other malignancy, with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "History of other malignancy",
                    "criterion": "history of other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If treated with a PD-1/aPD-L1 targeting or other immune-oncology agents in the past, excluded if had prior pneumonitis, prior Grade 3 or higher immune mediated toxicity, hypersensitivity to administered drug or drug related toxicity requiring discontinuation.",
            "criterions": [
                {
                    "exact_snippets": "excluded if had prior pneumonitis",
                    "criterion": "prior pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior Grade 3 or higher immune mediated toxicity",
                    "criterion": "immune mediated toxicity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity to administered drug",
                    "criterion": "hypersensitivity to administered drug",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "drug related toxicity requiring discontinuation",
                    "criterion": "drug related toxicity requiring discontinuation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of uncontrolled, clinically significant endocrinopathy.",
            "criterions": [
                {
                    "exact_snippets": "History of uncontrolled, clinically significant endocrinopathy",
                    "criterion": "endocrinopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.",
            "criterions": [
                {
                    "exact_snippets": "Unresolved Grade 2 or higher toxicities related to previous anticancer therapy",
                    "criterion": "toxicities related to previous anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        },
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recent history (within 6 months) of Childs-Pugh B or C classification of liver disease.",
            "criterions": [
                {
                    "exact_snippets": "Recent history (within 6 months) of Childs-Pugh B or C classification of liver disease.",
                    "criterion": "Childs-Pugh classification of liver disease",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated non-melanoma skin cancer",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "lentigo maligna without evidence of disease",
                    "criterion": "lentigo maligna",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "without evidence of disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease requiring systemic treatment in past 2-years (exceptions for endocrinopathies, vitiligo or atopic conditions).",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease requiring systemic treatment in past 2-years",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic treatment"
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "exceptions for endocrinopathies, vitiligo or atopic conditions",
                    "criterion": "autoimmune disease type",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "endocrinopathies",
                                "vitiligo",
                                "atopic conditions"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "For Monotherapy and Combination Dose Escalation:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "* History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.",
            "criterions": [
                {
                    "exact_snippets": "History of hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}